Navigation Links
Celsion Corporation Provides Business Update
Date:4/23/2013

LAWRENCEVILLE, N.J., April 23, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today is providing a business update, including the latest findings from its analysis of clinical trial results for ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin.  Celsion is evaluating ThermoDox® in a Phase III clinical trial for primary liver cancer (the HEAT Study), a Phase II clinical trial for colorectal liver metastasis and a Phase II clinical trial for recurrent chest wall breast cancer.

Phase III HEAT Study Data Analysis 

The Company has conducted a comprehensive analysis of the data from the Phase III HEAT Study with key principal investigators, data experts and liver cancer experts.  This follows the announcement on January 31, 2013, that ThermoDox® in combination with radiofrequency ablation (RFA) did not meet the study's primary endpoint.  Emerging data from the HEAT Study post analysis demonstrates that ThermoDox® markedly improves progression free survival (PFS) and overall survival (OS) in patients who had optimal RFA.  The analysis indicates that if patients' lesions undergo RFA for 45 minutes or more, they clearly benefitted from ThermoDox®.  These findings apply to HCC lesions from both size cohorts of the HEAT Study (3-5 cm and 5-7 cm) and represent a sizable subgroup of patients.  This data is subject to further verification and review by the HEAT Study Steering Committee. 

"We have completed a thorough review of the HEAT Study and there is clear evidence that ThermoDox® can benefit patients when RFA is optimized," said Dr. Nicholas Borys , Celsion's Vice President and Chief Medical Officer.  "These data are very exciting and consistent with the mechanism of ThermoDox&
'/>"/>

SOURCE Celsion Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Celsion Corporation Announces $15 Million Registered Direct Offering
2. Todays Research on Celsion, Zogenix, Actavis, and Avanir Pharma
3. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
4. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
5. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
6. Neogen Corporation Announces 2nd Quarter Results Conference Call
7. Luminex Corporation to Present at JP Morgan Healthcare Conference
8. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
9. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
10. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
11. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... YORK , Feb. 26, 2015 S&P ... Factual Stock Report coverage on MabVax Therapeutics Holdings ... (MBVX) is a clinical stage biotechnology company focused on ... unmet medical needs in the treatment of cancer. MabVax ... based on the protective immune responses generated by patients ...
(Date:2/26/2015)... , Feb. 26, 2015   Regulus Therapeutics ... company leading the discovery and development of innovative medicines ... , Ph.D., President and Chief Executive Officer of Regulus, ... Company 35 th Annual Healthcare Conference on Wednesday, ... is being held at the Boston Marriott Copley Place.  ...
(Date:2/26/2015)... 26, 2015  NuGene International, Inc. ("NuGene") (OTCQB: ... skin and hair rejuvenation, has announced that it ... record for investor relations and strategic communications. ... sales and diversification strategies – and we need ... shareholders," stated Ali Kharazmi CEO of NuGene when ...
(Date:2/26/2015)... Innovation is more urgent than ever. Radical business ... world and transforming global markets in industry after ... care, disruption is constantly underway. , As technology ... the foundations of established business models, large-scale innovation ... the next wave of mega-change. , This wave ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2
... Cord Blood America, Inc. (OTC Bulletin Board: CBAI), ... http://www.cordblood-america.com ) focused on bringing ... nationwide and internationally, today said it strongly supports legislation ... would require the Secretary of Health and Human Services ...
... VA Research is dedicated to restoring injured Veterans ... families, communities, and work places. For those who ... complications such as diabetes, VA researchers are designing ... technologies such as robotics, tissue engineering, and nanotechnology, ...
... CVD ) today reported earnings for its first quarter ... $0.76 per diluted share in the first quarter of 2008 ... gain on sale). "On a consolidated basis, first quarter net ... operating margin was 12.7%, and diluted EPS of $0.63 met ...
Cached Biology Technology:Cord Blood America Supports Effort in Congress to Inform on Value of Umbilical Cord Blood Stem Cell Storage 2Video: Turning Hope Into Reality - VA Research to Restore Veterans' Abilities 2Video: Turning Hope Into Reality - VA Research to Restore Veterans' Abilities 3Covance Reports First Quarter Revenue of $441M and EPS of $0.63; Updates Full Year Financial Targets 2Covance Reports First Quarter Revenue of $441M and EPS of $0.63; Updates Full Year Financial Targets 3Covance Reports First Quarter Revenue of $441M and EPS of $0.63; Updates Full Year Financial Targets 4Covance Reports First Quarter Revenue of $441M and EPS of $0.63; Updates Full Year Financial Targets 5Covance Reports First Quarter Revenue of $441M and EPS of $0.63; Updates Full Year Financial Targets 6Covance Reports First Quarter Revenue of $441M and EPS of $0.63; Updates Full Year Financial Targets 7Covance Reports First Quarter Revenue of $441M and EPS of $0.63; Updates Full Year Financial Targets 8Covance Reports First Quarter Revenue of $441M and EPS of $0.63; Updates Full Year Financial Targets 9Covance Reports First Quarter Revenue of $441M and EPS of $0.63; Updates Full Year Financial Targets 10Covance Reports First Quarter Revenue of $441M and EPS of $0.63; Updates Full Year Financial Targets 11Covance Reports First Quarter Revenue of $441M and EPS of $0.63; Updates Full Year Financial Targets 12
(Date:2/24/2015)... , Feb. 24, 2015 Research and ... the addition of the "Global 2D Gesture ... The analysts forecast the Global ... CAGR of 32.12% over the period 2014-2019 ... in non-traditional sectors is one of the major ...
(Date:2/12/2015)... Minn. , Feb. 12, 2015   ... company specializing in clinical study management systems, has ... Program , further distinguishing iMedNet ... Clinical Research Organizations (CROs) and healthcare consultants.  Building ... support, prospective customer referrals and numerous co-marketing opportunities), ...
(Date:2/5/2015)... Carolina , 5. Februar 2015 /PRNewswire/ ... als spezialisiertes Logistikunternehmen und hat eine neue ... klinische Logistikfirma (Clinical Logistics Organization – CLO) ... neuen Kampagne lautet First , mit ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3
... to a report issued last week by UNAIDS, access ... worldwide. But Dr. Groesbeck Parham, gynecologic oncologist and ... Center for Infectious Disease Research in Zambia (CIDRZ) warns ... dying of cervical cancer unless they have access to ...
... at The University of Manchester have developed a new x-ray ... and human cancers more effectively. Professor Robert Cernik and ... colour 3D X-ray system that allows material at each point ... work is reported in the latest issue of The Journal ...
... for commercial genetic testing is on the rise and ... (MGH) physician. In the December issue of Obstetrics ... testing is poorly regulated and may present potential pitfalls ... that are being offered have no proven clinical validity ...
Cached Biology News:Women with AIDS face cervical cancer threat 2New X-ray technique targets terrorists and tumors 2Direct-to-consumer advertising for genetic tests concerns physicians and may mislead patients 2
... The electrophoretic mobility shift assay (EMSA) ... interactions. Often referred to as gel shift ... on the principle that when subjected to ... a DNA-protein complex. The Pierce LightShift Chemiluminescent ...
... Lab Quantas unique combination of Coulter ... resolution capabilities and accurate cell counting. ... wavelengths, including UV, allowing flexible fluorochrome ... applications typically only achievable with larger, ...
... Genome-pULSe Kit delivers a novel procedure for ... labeling of whole genome DNA from small ... provide a quick and highly reproducible amplification ... consists of a REPLI-g Mini Kit module ...
... using PULSin may be superior to transfection ... traditional transfection, with PULSin you can study ... time course of proteins in cells. Likewise, ... information than traditional RNA interference experiments. ...
Biology Products: